Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3

@article{Magenta2007RosiglitazoneIM,
  title={Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3},
  author={Gabriela Magenta and Ximena Borenstein and Romina Rolando and Mar{\'i}a Adela Jasnis},
  journal={BMC Cancer},
  year={2007},
  volume={8},
  pages={47 - 47}
}
Activation of peroxisome proliferator-activated receptors γ (PPARγ) induces diverse effects on cancer cells. The thiazolidinediones (TZDs), such as troglitazone and ciglitazone, are PPARγ agonists exhibiting antitumor activities; however, the underlying mechanism remains inconclusive. Rosiglitazone (RGZ), a synthetic ligand of PPARγ used in the treatment of Type 2 diabetes, inhibits growth of some tumor cells and is involved in other processes related to cancer progression. Opposing results… CONTINUE READING
Highly Cited
This paper has 40 citations. REVIEW CITATIONS